Filing Flows › TherapeuticsMD (TXMD) › Q4 2025
TherapeuticsMD (TXMD) Q4 2025 earnings results (fourth quarter 2025)
10-K filed Mar 30, 2026
TherapeuticsMD (TXMD) reported revenue of $893K for the fourth quarter 2025 (Q4 2025), +34% from a year earlier and +14% from the quarter before. Operating margin was -173.8%, net loss $619K (69.3% of revenue).
TherapeuticsMD, Q4 2025: revenue $893K (+34% year over year), operating margin -173.8%, net loss $619K, operating cash flow $375K. The chart follows the revenue to costs, profit and cash.
| Q4 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $893K | +14% | +34% |
| Operating profit | −$1.6M | — | — |
| Net earnings | −$619K | -507% | -346% |
| Operating cash flow | $375K | -62% | 22× |
What changed
Revenue was $893K in Q4 2025, up 34% year over year and up 14% from the previous quarter.
Operating costs exceeded revenue by $1.6M, an operating margin of -173.8%. Total costs grew 85% against revenue growth of 34%. The fastest-growing cost line was General & admin (+89%). The quarter ended with a net loss of $619K, after a profit of $152K the previous quarter. Non-operating items added $1.0M, -168% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was $375K (up 2106% year over year). Non-cash charges added back $97K of depreciation and amortization and $51K of share-based compensation. Working capital and other items added $846K.
Questions
What was TherapeuticsMD's revenue in the fourth quarter 2025?
TherapeuticsMD (TXMD) reported revenue of $893K for the fourth quarter 2025 (Q4 2025), +34% from a year earlier and +14% from the quarter before.
Was TherapeuticsMD profitable in the fourth quarter 2025?
Operating loss was $1.6M (-173.8% of revenue) and net loss $619K.
Source: TherapeuticsMD 10-K on SEC EDGAR.